Iron(III) chloride hexahydrate does not enhance methotrexate cytotoxicity on Saccharomyces cerevisiae.
Methotrexate is a potent inhibitor of dihydropholate reductase that has been used as effective antineoplastic treatment due to its capacity to inhibit cell growth. In a previous work published in Bioelectrochemistry 2003;60:81-86, we reported a statistically significant increment of 40.1 and 29.4% in methotrexate potency when MCF-7 breast cancer cells were exposed simultaneously to iron(III) chloride hexahydrate (FeCl(3).6H(2)O) and methotrexate. The aim of this study was to investigate whether iron(III) could produce, on a Saccharomyces cerevisiae wild-type strain, alterations on methotrexate potency by the drop test survival assay and proliferation studies measured after 24 and 96 h of exposure. The data presented in the current report indicate that FeCl(3).6H(2)O (1, 10, 100 and 500 microg/ml) does not induce modulation of the action of methotrexate (10, 100 and 500 microg/ml) in S. cerevisiae yeast cells when they are exposed simultaneously for 24 and 96 h.
Ruiz-Gómez
M J
MJ
Laboratory of Radiobiology, Department of Radiology and Physical Medicine, Faculty of Medicine, University of Malaga, Teatinos s/n, Malaga, Spain.
Martínez-Morillo
M
M
D000964:Antimetabolites, Antineoplastic / Q000633:toxicity*; D002470:Cell Survival / Q000187:drug effects*; D004357:Drug Synergism; D005290:Ferric Compounds / Q000633:toxicity*; D008727:Methotrexate / Q000633:toxicity*; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000254:growth & development
D000964:Antimetabolites, Antineoplastic; D005290:Ferric Compounds; D008727:Methotrexate